Privium Fund Management B.V. Sells 138,263 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Privium Fund Management B.V. lessened its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 22.6% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 473,951 shares of the biotechnology company’s stock after selling 138,263 shares during the period. Arrowhead Pharmaceuticals makes up 2.9% of Privium Fund Management B.V.’s portfolio, making the stock its 9th largest position. Privium Fund Management B.V.’s holdings in Arrowhead Pharmaceuticals were worth $16,347,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Arizona State Retirement System grew its position in Arrowhead Pharmaceuticals by 1.9% in the 3rd quarter. Arizona State Retirement System now owns 32,661 shares of the biotechnology company’s stock valued at $1,126,000 after buying an additional 620 shares during the last quarter. Summit Global Investments acquired a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $343,000. Federated Hermes Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $52,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $287,000. Finally, CIBC Asset Management Inc purchased a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at approximately $317,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Insider Activity

In related news, Director Adeoye Y. Olukotun sold 10,000 shares of the business’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $67.66, for a total value of $676,600.00. Following the completion of the transaction, the director owned 33,600 shares of the company’s stock, valued at approximately $2,273,376. The trade was a 22.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Christopher Richard Anzalone sold 13,187 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $66.10, for a total transaction of $871,660.70. Following the sale, the chief executive officer directly owned 3,792,739 shares in the company, valued at $250,700,047.90. This represents a 0.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 510,836 shares of company stock worth $33,603,060 in the last quarter. Corporate insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, January 21st. HC Wainwright boosted their price objective on shares of Arrowhead Pharmaceuticals from $85.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, January 21st. Bank of America increased their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. B. Riley lifted their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.67.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR opened at $69.33 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. The business’s fifty day moving average price is $65.21 and its two-hundred day moving average price is $41.65. The stock has a market cap of $9.71 billion, a PE ratio of -866.52 and a beta of 1.21. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $76.76.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.